Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Mavroudis, D' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 60 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Alexopoulos, A; Kouroussis, C; Malamos, N; Kakolyris, S; Kalbakis, K; Kosmas, C; Mavroudis, D; Agelaki, S; Vlachonicolis, J; Sarra, E; Rigatos, G; Georgoulias, V
      Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study

      ANNALS OF ONCOLOGY
    2. Mavroudis, D; Papadakis, E; Veslemes, M; Tsiafaki, X; Stavrakakis, J; Kouroussis, C; Kakolyris, S; Bania, E; Jordanoglou, J; Agelidou, M; Vlachonicolis, J; Georgoulias, V
      A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

      ANNALS OF ONCOLOGY
    3. Kakolyris, S; Mavroudis, D; Tsavaris, N; Souglakos, J; Tsiafaki, P; Kalbakis, K; Agelaki, S; Androulakis, N; Georgoulias, V
      Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study

      ANNALS OF ONCOLOGY
    4. Stathopoulos, GP; Mavroudis, D; Tsavaris, N; Kouroussis, C; Aravantinos, G; Agelaki, S; Kakolyris, S; Rigatos, SK; Karabekios, S; Georgoulias, V
      Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer

      ANNALS OF ONCOLOGY
    5. Samonis, G; Anatoliotaki, M; Apostolakou, H; Maraki, S; Mavroudis, D; Goergoulias, V
      Transient fungemia due to Rhodotorula rubra in a cancer patient: Case report and review of the literature

      INFECTION
    6. Kouroussis, C; Kakolyris, S; Mavroudis, D; Androulakis, N; Kalbakis, K; Agelaki, S; Sarra, E; Souglakos, J; Christodoulakis, M; Samonis, G; Georgoulias, V
      A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    7. Agelaki, S; Kakolyris, S; Palamidas, P; Kouroussis, C; Mavroudis, D; Kalbakis, K; Georgoulias, V; Raptis, A
      A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer

      LUNG CANCER
    8. Kakolyris, S; Kouroussis, C; Souglakos, J; Mavroudis, D; Agelaki, S; Kalbakis, K; Androulakis, N; Vardakis, N; Vamvakas, L; Georgoulias, V
      A phase I clinical trial of topotecan given every 2 weeks in patients withrefractory solid tumors

      ONCOLOGY
    9. Kouroussis, C; Souglakos, J; Kakolyris, S; Mavroudis, D; Malamos, N; Kalbakis, K; Androulakis, N; Agelaki, A; Vardakis, N; Samonis, G; Georgoulias, V
      Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study

      ONCOLOGY
    10. Kakolyris, S; Souglakos, J; Kouroussis, C; Androulakis, N; Mavroudis, D; Kalbakis, K; Kotsakis, A; Vardakis, N; Koukourakis, M; Romanos, J; Georgoulias, V
      A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer

      ONCOLOGY
    11. Kalbakis, K; Kouroussis, C; Kakolyris, S; Mavroudis, D; Souglakos, J; Agelaki, S; Vamvakas, L; Christodoulakis, M; Stylianou, K; Georgoulias, V
      Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes

      BRITISH JOURNAL OF CANCER
    12. Giannakakis, T; Ziras, N; Kakolyris, S; Mavroudis, D; Androulakis, N; Agelaki, S; Parashos, M; Sarra, E; Dimou, T; Hatzidaki, D; Vlachonikolis, J; Georgoulias, V
      Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study

      EUROPEAN JOURNAL OF CANCER
    13. Kakolyris, S; Kouroussis, C; Kalbakis, K; Mavroudis, D; Souglakos, J; Vardakis, N; Kremos, S; Georgoulias, V
      Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin

      ANNALS OF ONCOLOGY
    14. Mavroudis, D; Alexopoulos, A; Ziras, N; Malamos, N; Kouroussis, C; Kakolyris, S; Agelaki, S; Kalbakis, K; Tsavaris, N; Potamianou, A; Rigatos, G; Georgoulias, V
      Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study

      ANNALS OF ONCOLOGY
    15. Kouroussis, C; Agelaki, S; Mavroudis, D; Souglakos, J; Kakolyris, S; Kalbakis, K; Vardakis, N; Reppa, D; Hatzidaki, D; Samonis, G; Georgoulias, V
      A dose escalation study of weekly docetaxel in patients with advanced solid tumors

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    16. Mavroudis, D; Kourousis, C; Androulakis, N; Kalbakis, K; Agelaki, S; Kakolyris, S; Souglakos, J; Sarra, E; Vardakis, N; Hatzidaki, D; Sarmonis, G; Georgoulias, V
      Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF) - A phase II trial

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    17. Kakolyris, S; Souglakos, J; Agelaki, S; Kourousis, C; Mavroudis, D; Sarra, E; Malliotakis, P; Georgoulias, V
      A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy

      LUNG CANCER
    18. Mavroudis, D; Kourousis, C; Kakolyris, S; Agelaki, S; Kalbakis, K; Androulakis, N; Souglakos, J; Vardakis, N; Samonis, G; Georgoulias, V
      Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report

      SEMINARS IN ONCOLOGY
    19. Barrett, J; Mavroudis, D
      Prevention of acute graft-versus-host disease by delayed or selected lymphocyte add back

      HEMATOPOIETIC STEM CELL TRANSPLANTION
    20. Mavroudis, D; Barrett, J
      Separating GVHD and GVL reactions

      ALLOGENEIC IMMUNOTHERAPY FOR MALIGNANT DISEASES
    21. Kouroussis, C; Xydakis, E; Potamianou, A; Giannakakis, T; Kakolyris, S; Agelaki, S; Sara, E; Malamos, N; Alexopoulos, A; Mavroudis, D; Samonis, G; Papadouris, S; Georgoulias, V; Panagos, G
      Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study

      ANNALS OF ONCOLOGY
    22. Mavroudis, D; Malamos, N; Alexopoulos, A; Kourousis, C; Agelaki, S; Sarra, E; Potamianou, A; Kosmas, C; Rigatos, G; Giannakakis, T; Kalbakis, K; Apostolaki, F; Vlachonicolis, J; Kakolyris, S; Samonis, G; Georgoulias, V
      Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial

      ANNALS OF ONCOLOGY
    23. Kouroussis, C; Androulakis, N; Kakolyris, S; Souglakos, J; Kotsakis, T; Mavroudis, D; Katsogridakis, K; Vardakis, N; Hatzidaki, D; Samonis, G; Vlachonikolis, J; Georgoulias, V
      Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    24. Raptis, A; Mavroudis, D; Suffredini, AF; Molldrem, J; Van Rhee, F; Childs, R; Phang, S; Barrett, AJ
      High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients

      BONE MARROW TRANSPLANTATION
    25. Hensel, N; Agarwala, V; Jiang, YZ; Mavroudis, D; Molldrem, J; Barrett, AJ
      A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method

      BONE MARROW TRANSPLANTATION
    26. van Rhee, F; Jiang, YZ; Vigue, F; Kirby, M; Mavroudis, D; Hensel, NF; Agarwala, V; Clave, E; Childs, R; Raptis, A; Sloand, E; Carter, C; Read, EJ; Barrett, J
      Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells callstimulate allogeneic T-cell responses: implications for graft rejection inmismatched transplantation

      BRITISH JOURNAL OF HAEMATOLOGY
    27. MAVROUDIS D; MALAMOS N; GIANNAKAKIS T; ALEXOPOULOS A; POTAMIANOU A; RIGATOS G; KOSMAS C; SARRA E; PAPADOURIS S; GEORGOULIAS V
      SALVAGE CHEMOTHERAPY OF METASTATIC BREAST-CANCER WITH DOCETAXEL AND GEMCITABINE - A MULTICENTER PHASE-II TRIAL

      Annals of oncology
    28. PANAGOS G; MAVROUDIS D; POTAMIANOU A; MALAMOS N; KOUROUSIS C; KAKOLYRIS S; SOUGLAKOS J; SARRA E; GIANNAKAKIS T; GEORGOULIAS V
      PHASE-I STUDY OF DOCETAXEL AND EPIRUBICIN IN ADVANCED BREAST-CANCER

      Annals of oncology
    29. ZIRAS N; GIANAKAKIS T; ANDROULAKIS N; MAVROUDIS D; KAKOLYRIS S; TSITOURA P; KOUROUSIS C; SOUGLAKOS J; PERISINAKI G; GEORGOULIAS V
      2ND LINE TREATMENT OF METASTATIC COLON CARCINOMAS WITH OXALIPLATIN AND HIGH-DOSE 5-FLUOROURACIL AND FOLINIC ACID - A PRELIMINARY-REPORT OF A CONFIRMATORY PHASE-II TRIAL OF THE GREEK COOPERATIVE GROUP FOR THE STUDY OF COLORECTAL-CANCER

      Annals of oncology
    30. RAPTIS A; MAVROUDIS D; MOLLDREM J; TISDALE J; YOUNG NS; PHANG S; BARRETT AJ
      TREATMENT OF LEUKEMIC RELAPSE FOLLOWING BONE-MARROW TRANSPLANTATION

      Annals of oncology
    31. KAKOLYRIS S; KOUROUSSIS C; SOUGLAKOS J; ANDROULAKIS N; MAVROUDIS D; KALBAKIS K; KOTSAKIS A; SARA E; AGELAKI S; SAMONIS G; GEORGOULIAS V
      PHASE-I STUDY OF IRINOTECAN (CPT-11) AND CISPLATIN (CDDP) COMBINATIONIN METASTATIC NONSMALL CELL LUNG-CANCER (NSCLC)

      Annals of oncology
    32. AGELAKI S; MAVROUDIS D; KAKOLYRIS S; KOUROUSIS C; KALBAKIS K; SARRA E; SOUGLAKOS J; KALIKAKI T; PERISINAKI G; GEORGOULIAS V
      PHASE-I STUDY OF WEEKLY PLACLITAXEL IN ADVANCED SOLID TUMORS - A PRELIMINARY-REPORT

      Annals of oncology
    33. BARRETT AJ; MAVROUDIS D; TISDALE J; MOLLDREM J; CLAVE E; DUNBAR C; COTTLERFOX M; PHANG S; CARTER C; OKUNNIEFF P; YOUNG NS; READ EJ
      T-CELL-DEPLETED BONE-MARROW TRANSPLANTATION AND DELAYED T-CELL ADD-BACK TO CONTROL ACUTE GVHD AND CONSERVE A GRAFT-VERSUS-LEUKEMIA EFFECT

      Bone marrow transplantation
    34. MOLLDREM JJ; JIANG YZ; STETLERSTEVENSON M; MAVROUDIS D; HENSEL N; BARRETT AJ
      HEMATOLOGICAL RESPONSE OF PATIENTS WITH MYELODYSPLASTIC SYNDROME TO ANTITHYMOCYTE GLOBULIN IS ASSOCIATED WITH A LOSS OF LYMPHOCYTE-MEDIATEDINHIBITION OF CFU-GM AND ALTERATIONS IN T-CELL RECEPTOR V-BETA PROFILES

      British Journal of Haematology
    35. DERMIME S; MAVROUDIS D; JIANG YZ; HENSEL N; MOLLDREM J; BARRETT AJ
      IMMUNE ESCAPE FROM A GRAFT-VERSUS-LEUKEMIA EFFECT MAY PLAY A ROLE IN THE RELAPSE OF MYELOID LEUKEMIAS FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION

      Bone marrow transplantation
    36. MOLLDREM JJ; CAPLES M; MAVROUDIS D; PLANTE M; YOUNG NS; BARRETT AJ
      ANTITHYMOCYTE GLOBULIN FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME

      British Journal of Haematology
    37. MOLLDREM JJ; CLAVE E; JIANG YZ; MAVROUDIS D; RAPTIS A; HENSEL N; AGARWALA V; BARRETT AJ
      CYTOTOXIC T-LYMPHOCYTES SPECIFIC FOR A NONPOLYMORPHIC PROTEINASE-3 PEPTIDE PREFERENTIALLY INHIBIT CHRONIC MYELOID-LEUKEMIA COLONY-FORMING-UNITS

      Blood
    38. RAPTIS A; MAVROUDIS D; JIANG YZ; VANRHEE F; MOLLDREM J; BARRETT AJ
      P21 IS SPECIFICALLY INHIBITED IN THE INITIAL PHASE OF THE MIXED LYMPHOCYTE-REACTION

      Blood
    39. JIANG YZ; MOLLDREM J; CLAVE E; MAVROUDIS D; BARRETT AJ
      RESPONSE TO ANTITHYMOCYTE GLOBULIN (ATG) TREATMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IS ASSOCIATED WITH REDUCED CLONALITY OF THE TCR V-BETA REPERTOIRE

      Blood
    40. RAPTIS A; MAVROUDIS D; CLAVE E; VANRHEE F; CHILDS R; BARRETT AJ
      POLYMORPHISM OF THE CD34 GENE DOES NOT RESULT IN THE PRODUCTION OF ANALLELIC PROTEIN

      Blood
    41. RAPTIS A; MAVROUDIS D; MOLLDREM J; CHILDS R; LEDAKIS P; BAHCECI E; VANRHEE F; HENSEL N; PHANG S; BARRETT AJ
      HIGH-DOSE METHYLPREDNISOLONE IMPROVES OUTCOME OF DIFFUSE ALVEOLAR HEMORRHAGE (DAH) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) FOR HEMATOLOGICAL MALIGNANCIES

      Blood
    42. MOLLDREM J; CAPLES M; MAVROUDIS D; YOUNG NS; BARRETT AJ
      TREATMENT WITH ANTITHYMOCYTE GLOBULIN (ATG) INDUCES SUSTAINED TRANSFUSION INDEPENDENCE IN PATIENTS WITH REFRACTORY-ANEMIA AND MYELODYSPLASTIC SYNDROME

      Blood
    43. MOLLDREM JJ; JIANG YZ; MAVROUDIS D; RAPTIS A; HENSEL N; BARRETT AJ
      HEMATOLOGICAL RESPONSE OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) TO ANTITHYMOCYTE GLOBULIN (ATG) TREATMENT IS ASSOCIATED WITH A LOSS OF CD8-CELL MEDIATED CFU-GM INHIBITION( T)

      Blood
    44. BARRETT AJ; READ EJ; VIGUE F; MAVROUDIS D; CARTER C; DUNBAR C; PHANG S; BENYUNES M; JACOBS C; YOUNG NS
      RAPID HEMATOLOGICAL RECOVERY WITHOUT GRAFT-VS-HOST DISEASE (GVHD) FOLLOWING G-CSF-MOBILIZED T-CELL DEPLETED ALLOGENEIC PERIPHERAL-BLOOD PRECURSOR CELL (PBPC) TRANSPLANTS FOR HEMATOLOGICAL MALIGNANCY

      Blood
    45. BARRETT AJ; MAVROUDIS D; READ EJ; MOLLDREM J; DUNBAR C; CARTER C; PHANG S
      GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) MODIFIED, T-CELL DEPLETED ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCYIMPROVES CD34+ CELL YIELD BUT CAUSES DELAYED PANCYTOPENIA

      Blood
    46. JIANG YZ; CLAVE E; MOLLDREM J; RAPTIS A; VANRHEE F; MAVROUDIS D; HENSEL N; BARRETT AJ
      BONE-MARROW AND BLOOD SHOW CONSISTENT DIFFERENCES IN THE T-CELL RECEPTOR (TCR) V-BETA REPERTOIRE

      Blood
    47. MOLLDREM JJ; MAVROUDIS D; JIANG YZ; DERMIME S; STETLERSTEVENSON MA; AMEN MJ; BARRETT AJ
      HEMATOLOGICAL RESPONSE IN CYCLOSPORINE-TREATED T-CELL LARGE GRANULAR LYMPHOCYTIC-LEUKEMIA (T-LGL) CORRELATES WITH AN INCREASE KILLER INHIBITORY RECEPTOR (KIR) EXPRESSION AND LOSS OF CFU-GM INHIBITION

      Blood
    48. RAPTIS A; CLAVE E; MAVROUDIS D; VANRHEE F; HENSEL N; LEDAKIS P; MOLLDREM J; BARRETT AJ
      POLYMORPHISM OF THE LEUKOCYTE DIFFERENTIATION ANTIGEN CD33 - A MYELOID-RESTRICTED MINOR ANTIGEN

      Blood
    49. JIANG YZ; MAVROUDIS D; DERMIME S; HENSEL N; COURIEL D; MOLLDREM J; BARRETT AJ
      ALLOREACTIVE CD4(-LYMPHOCYTES CAN EXERT CYTOTOXICITY TO CHRONIC MYELOID-LEUKEMIA CELLS PROCESSING AND PRESENTING EXOGENOUS ANTIGEN() T)

      British Journal of Haematology
    50. LEWALLE P; HENSEL N; GUIMARAES A; COURIEL D; JIANG YZ; MAVROUDIS D; BARRETT AJ
      HELPER AND CYTOTOXIC LYMPHOCYTE-RESPONSES TO CHRONIC MYELOID-LEUKEMIA- IMPLICATIONS FOR ADOPTIVE IMMUNOTHERAPY WITH T-CELLS

      British Journal of Haematology
    51. MAVROUDIS D; READ E; COTTLERFOX M; COURIEL D; MOLLDREM J; CARTER C; YU M; DUNBAR C; BARRETT J
      CD34(+) CELL DOSE PREDICTS SURVIVAL, POSTTRANSPLANT MORBIDITY, AND RATE OF HEMATOLOGIC RECOVERY AFTER ALLOGENEIC MARROW TRANSPLANTS FOR HEMATOLOGIC MALIGNANCIES

      Blood
    52. MOLLDREM J; DERMIME S; PARKER K; JIANG YZ; MAVROUDIS D; HENSEL N; FUKUSHIMA P; BARRETT AJ
      TARGETED T-CELL THERAPY FOR HUMAN LEUKEMIA - CYTOTOXIC T-LYMPHOCYTES SPECIFIC FOR A PEPTIDE DERIVED FROM PROTEINASE-3 PREFERENTIALLY LYSE HUMAN MYELOID-LEUKEMIA CELLS

      Blood
    53. BARRETT AJ; MAVROUDIS D; MOLLDREM J; COURIEL D; YOUNG NS
      IMMUNE MODULATION TO TREAT LEUKEMIC RELAPSE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION - A RISK-BASED SEQUENTIAL APPROACH

      Blood
    54. MOLLDREM J; STETLERSTEVENSON M; MAVROUDIS D; YOUNG NS; BARRETT AJ
      ANTITHYMOCYTE GLOBULIN (ATG) ABROGATES CYTOPENIAS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

      Blood
    55. BARRETT AJ; MAVROUDIS D; MOLLDREM J; READ EJ; CARTER C; DUNBAR C; YOUNG NS
      OPTIMIZING THE DOSE AND TIMING OF LYMPHOCYTE ADD-BACK IN T-CELL DEPLETED BMT BETWEEN HLA-IDENTICAL SIBLINGS

      Blood
    56. DERMIME S; MAVROUDIS D; JIANG YZ; HENSEL N; MOLLDREM J; BARRETT AJ
      IMMUNE ESCAPE FROM A GRAFT-VERSUS-LEUKEMIA EFFECT PLAY A ROLE IN THE RELAPSE OF MYELOGENOUS LEUKEMIAS FOLLOWING ALLOGENEIC DONE MARROW TRANSPLANTATION

      Blood
    57. DERMIME S; MOLLDREM J; PARKER KC; JIANG YZ; MAVROUDIS D; HENSEL N; COURIEL D; MAHONEY M; COLIGAN JE; BARRETT AJ
      HUMAN CD8(-LYMPHOCYTES RECOGNIZE THE FUSION REGION OF BCR() T)ABL HYBRID PROTEIN PRESENT IN CHRONIC MYELOGENOUS LEUKEMIA/

      Blood
    58. COURIEL D; CANOSA J; ENGLER H; MOLLDREM J; MAVROUDIS D; DUNBAR C; COLLINS A; WESLEY B; BARRETT AJ
      FACTORS PREDICTING OUTCOME FOLLOWING REACTIVATION OF CYTOMEGALOVIRUS AFTER T-DEPLETED BMT FOR HEMATOLOGICAL MALIGNANCY

      Blood
    59. COURIEL D; MAHONEY M; HENSEL N; MAVROUDIS D; JIANG YZ; DERMIME S; MOLLDREM J; BARRETT AJ
      DONOR-VERSUS-RECIPIENT HELPER T-LYMPHOCYTE PRECURSOR NUMBERS GIVEN BUT NOT THEIR FREQUENCY PREDICTS GVHD IN HLA MATCHED SIBLING BMT

      Blood
    60. MOLLDREM J; DERMIME S; PARKER K; COURIEL D; HENSEL N; JIANG YZ; MAVROUDIS D; MAHONEY M; BARRETT J
      CYTOTOXIC T-CELLS SHOW SPECIFICITY TO MHC CLASS I-RESTRICTED PEPTIDE DERIVED FROM PROTEINASE-3, A LEUKEMIA-ASSOCIATED PROTEIN

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 03:26:42